MISCAN: Estimating lead-time and over-detection by simulation

BJU International, Supplement

Volumn 92, Issue 2, 2003, Pages 106-111

  Draisma, G ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; DISEASE SIMULATION; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY;

AGED; BIOPSY; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC ERRORS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 0346495995     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE. Screening decreases prostate cancer death, first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91
2. Candas B, Cusan L, Gomez JL et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000; 45: 19-35
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54
4. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ 2002; 166: 586-91
5. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol. Austria Urol 2001; 58: 417-24
6. Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer - part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-24
7. Feuer EJ, Merrill RM, Hankey BJ. Cancer surveillance series: Interpreting trends in prostate cancer - Part II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1025-32
8. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the 'PSA ERA'. Int J Cancer 2001; 92: 893-8
9. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21: 251S-272S
10. De Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-44
11. Beemsterboer PMM, Kranse R, de Koning HJ, Habbema JDF, Schröder FH. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer (Pred Oncol) 1999; 84: 437-41
12. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Meth Programs Biomed 1985; 20: 79-93
13. De Koning HJ, Boer R, Warmerdam PG, Beemsterboer PMM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials. J Natl Cancer Inst 1995; 87: 1217-23
14. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening. Comput Biomed Res 1999; 32: 13-33
15. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78
16. Franks LM. Latent carcinoma of the prostate. J Path Bact 1954; 68: 603-16
17. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-85
18. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742-6
19. Watanabe M, Nakayame T, Shiraishi T, Stemmermann GN, Yatani R. Comparative study of prostate cancer in Japan versus the United States; A Review. Urol Oncol 2000; 5: 274-83
20. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775-85
21. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594-8
22. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
23. Hugosson J, Aus G, Carlsson S et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000; 85: 1078-84
24. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994; 152: 1743-8
25. Auvinen A, Maattanen L, Stenman UH, Tammela T, Ranniko S, Aro J. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279-85
26. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis in prostate specific antigen screening; Lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90
27. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening. an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998; 9: 1297-300
28. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening, followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 2189-91
29. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159: 1368-72